TY - JOUR
T1 - Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics
AU - Jiang, Shanshan
AU - Rui, Qihong
AU - Wang, Yu
AU - Heo, Hye Young
AU - Zou, Tianyu
AU - Yu, Hao
AU - Zhang, Yi
AU - Wang, Xianlong
AU - Du, Yongxing
AU - Wen, Xinrui
AU - Chen, Fangyao
AU - Wang, Jihong
AU - Eberhart, Charles G.
AU - Zhou, Jinyuan
AU - Wen, Zhibo
N1 - Publisher Copyright:
© 2017, European Society of Radiology.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Objectives: To explore the feasibility of using amide proton transfer-weighted (APTw) MRI metrics as surrogate biomarkers to identify the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status in glioblastoma (GBM). Methods: Eighteen newly diagnosed GBM patients, who were previously scanned at 3T and had a confirmed MGMT methylation status, were retrospectively analysed. For each case, a histogram analysis in the tumour mass was performed to evaluate several quantitative APTw MRI metrics. The Mann-Whitney test was used to evaluate the difference in APTw parameters between MGMT methylated and unmethylated GBMs, and the receiver-operator-characteristic analysis was further used to assess diagnostic performance. Results: Ten GBMs were found to harbour a methylated MGMT promoter, and eight GBMs were unmethylated. The mean, variance, 50th percentile, 90th percentile and Width10-90 APTw values were significantly higher in the MGMT unmethylated GBMs than in the MGMT methylated GBMs, with areas under the receiver-operator-characteristic curves of 0.825, 0.837, 0.850, 0856 and 0.763, respectively, for the discrimination of MGMT promoter methylation status. Conclusions: APTw signal metrics have the potential to serve as valuable imaging biomarkers for identifying MGMT methylation status in the GBM population. Key Points: • APTw-MRI is applied to predict MGMT promoter methylation status in GBMs. • GBMs with unmethylated MGMT promoter present higher APTw-MRI than methylated GBMs. • Multiple APTw histogram metrics can identify MGMT methylation status. • Mean APTw values showed the highest diagnostic accuracy (AUC = 0.825).
AB - Objectives: To explore the feasibility of using amide proton transfer-weighted (APTw) MRI metrics as surrogate biomarkers to identify the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status in glioblastoma (GBM). Methods: Eighteen newly diagnosed GBM patients, who were previously scanned at 3T and had a confirmed MGMT methylation status, were retrospectively analysed. For each case, a histogram analysis in the tumour mass was performed to evaluate several quantitative APTw MRI metrics. The Mann-Whitney test was used to evaluate the difference in APTw parameters between MGMT methylated and unmethylated GBMs, and the receiver-operator-characteristic analysis was further used to assess diagnostic performance. Results: Ten GBMs were found to harbour a methylated MGMT promoter, and eight GBMs were unmethylated. The mean, variance, 50th percentile, 90th percentile and Width10-90 APTw values were significantly higher in the MGMT unmethylated GBMs than in the MGMT methylated GBMs, with areas under the receiver-operator-characteristic curves of 0.825, 0.837, 0.850, 0856 and 0.763, respectively, for the discrimination of MGMT promoter methylation status. Conclusions: APTw signal metrics have the potential to serve as valuable imaging biomarkers for identifying MGMT methylation status in the GBM population. Key Points: • APTw-MRI is applied to predict MGMT promoter methylation status in GBMs. • GBMs with unmethylated MGMT promoter present higher APTw-MRI than methylated GBMs. • Multiple APTw histogram metrics can identify MGMT methylation status. • Mean APTw values showed the highest diagnostic accuracy (AUC = 0.825).
KW - Amide proton transfer-weighted imaging
KW - Glioblastoma
KW - Magnetic resonance imaging
KW - Methylation
KW - O6-methylguanine-DNA methyltransferase
UR - http://www.scopus.com/inward/record.url?scp=85037732562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037732562&partnerID=8YFLogxK
U2 - 10.1007/s00330-017-5182-4
DO - 10.1007/s00330-017-5182-4
M3 - Article
C2 - 29234914
AN - SCOPUS:85037732562
SN - 0938-7994
VL - 28
SP - 2115
EP - 2123
JO - European Radiology
JF - European Radiology
IS - 5
ER -